List of Excipients in Branded Drug EVAMIST

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Padagis US LLC	EVAMIST	estradiol	0574-2067	ALCOHOL
Padagis US LLC	EVAMIST	estradiol	0574-2067	OCTISALATE
Physicians Total Care Inc	EVAMIST	estradiol	54868-6157	ALCOHOL

Evamist Excipient Strategy and Commercial Opportunities in Estradiol Transdermal Spray

Last updated: August 11, 2026

Evamist is a metered-dose transdermal estradiol spray built around a volatile ethanol vehicle, octisalate and povidone. Its commercial value lies in the delivery system rather than estradiol itself. The main opportunities are generic or authorized-generic substitution, improved spray devices, lower-transfer formulations, preservative and skin-tolerability optimization, and differentiated low-dose menopause products.

Evamist contains 1.53 mg of estradiol per 90-microliter spray and delivers approximately 90 micrograms of estradiol per actuation. The approved indication is treatment of moderate-to-severe vasomotor symptoms associated with menopause. The product is applied once daily to the inner forearm, with dose escalation permitted under the prescribing information.[1]

What excipients are used in Evamist?

Evamist uses alcohol, octisalate and povidone as inactive ingredients. Each excipient contributes to the performance of the transdermal delivery system.[1]

Component	Likely formulation role	Commercial significance
Ethanol	Solvent, volatile vehicle and rapid-drying carrier	Controls solubility, evaporation and initial skin deposition
Octisalate	Skin-permeation component and formulation aid	May improve estradiol flux and support delivery through the stratum corneum
Povidone	Film-forming, solubilizing and viscosity-modifying polymer	Can influence residual film, dose uniformity and skin adhesion
Estradiol	Active pharmaceutical ingredient	Requires precise low-dose delivery and protection from transfer

The label establishes composition but does not assign a complete mechanistic function to each excipient. Functional attribution must be confirmed through formulation development, skin-permeation testing, microscopy, residual-film analysis and comparative bioavailability studies.

Why ethanol is central to the formulation

Ethanol provides a practical vehicle for dissolving estradiol and producing a spray that dries rapidly on skin. Evaporation increases the local concentration of estradiol and may improve partitioning into the stratum corneum. The same mechanism creates commercial constraints:

• high ethanol content can cause stinging or dryness;
• evaporation can change delivered dose if the device is poorly calibrated;
• flammability affects packaging, transportation and handling;
• dose can vary with priming, actuator performance and residual product in the valve or pump;
• ethanol can increase transfer risk before the application site dries.

A follow-on product that lowers ethanol content must preserve estradiol solubility, sprayability, drying time and skin permeation. A lower-alcohol formulation may improve tolerability but could require a new permeation strategy.

Why octisalate matters

Octisalate, also known as ethylhexyl salicylate, is commonly used as a UV-filtering ingredient. In Evamist, it is part of the transdermal formulation and may affect estradiol partitioning into skin. Its presence creates a potential differentiation point because the excipient is not simply a conventional aqueous vehicle component.

A developer seeking an equivalent product must assess:

• octisalate concentration;
• its role in estradiol solubilization;
• its effect on flux and depot formation in skin;
• residual surface concentration after drying;
• photostability and packaging compatibility;
• impurity and degradation-product profiles.

Replacing octisalate with another penetration enhancer could create a clinically different product even if estradiol strength remains unchanged.

Why povidone matters

Povidone can improve solubilization and help form a thin residual film after ethanol evaporation. Its molecular weight and concentration may affect spray viscosity, atomization, drying and dose uniformity. A different grade of povidone, or substitution with a polymer such as hydroxypropyl cellulose or polyvinyl alcohol, could produce a more durable film but also increase tack, residue or transfer.

For an abbreviated new drug application, the applicant must determine whether the change is compatible with the applicable reference-product requirements. For a 505(b)(2) product, the applicant may have greater formulation flexibility but could face additional clinical or bridging requirements.

What formulation patents protect Evamist?

Evamist’s defensibility has historically depended on formulation and transdermal-delivery technology rather than on a durable composition-of-matter patent for estradiol. Estradiol is an old, well-characterized small molecule with extensive prior art.

Relevant protection categories include:

1. transdermal compositions containing estradiol and a volatile alcohol;
2. penetration-enhancer systems;
3. spray or metered-dose delivery systems;
4. dosing regimens for menopausal symptoms;
5. application-site and transfer-control instructions;
6. manufacturing processes that control dose uniformity and spray characteristics.

The FDA Orange Book is the controlling public source for patents listed against an approved NDA. Patent status should be evaluated by NDA number, listed patent number, delisting status, expiration, pediatric extensions and any applicable statutory exclusivity. Evamist is associated with NDA 022039 in FDA product records.[2]

A commercial entrant should not assume that the expiration of an early formulation patent eliminates all barriers. Later patents can cover:

• a narrower excipient ratio;
• a particular actuator or container;
• spray particle-size distribution;
• drying-time limits;
• low-dose titration;
• methods that reduce secondary transfer;
• manufacturing controls for estradiol content per actuation.

Patent claims directed solely to excipient selection may be vulnerable if the ingredients and functions were predictable. Claims supported by comparative skin-flux data, improved dose consistency or reduced transfer may present stronger enforcement positions.

When does Evamist lose exclusivity and what generic entry risks exist?

Evamist does not have biosimilar risk because estradiol is a small-molecule active ingredient. Competition would proceed through an ANDA, a 505(b)(2) application, or potentially a marketed generic product relying on established regulatory pathways.

The principal entry risks are:

Risk category	Effect on a generic or follow-on product
Orange Book patent challenge	May require a Paragraph IV certification and litigation management
Formulation differences	Can affect bioequivalence, skin flux and local tolerability
Device equivalence	Metered-dose performance may prevent a simple formulation substitution
Transfer behavior	A different drying film can alter exposure to caregivers, partners or children
Low commercial volume	May reduce the incentive to develop a spray rather than a patch or gel
Prescribing inertia	Clinicians may substitute lower-cost estradiol patches or gels
Manufacturing complexity	Specialized filling and actuator controls increase capital requirements

A Paragraph IV challenge would typically focus on invalidity, non-infringement or unenforceability of listed patents. For a transdermal spray, the applicant also must manage device and formulation issues that are less prominent in conventional oral tablets.

The relevant competitive threat is broader than a direct Evamist generic. Estradiol patches, gels, emulsions, creams and vaginal products can capture prescriptions without reproducing the spray formulation. The product therefore competes in a therapeutic class with multiple established delivery formats.

What FDA regulatory pathway applies to an Evamist generic?

A conventional generic applicant would generally pursue an ANDA under section 505(j) if it can meet the required sameness and equivalence standards. A materially different formulation, delivery device or dosing method may require a 505(b)(2) application.

ANDA strategy

An ANDA applicant would normally seek to match:

• active ingredient and strength;
• dosage form and route;
• metered dose per actuation;
• labeled dosing instructions;
• inactive-ingredient composition where relevant;
• container-closure and actuator performance;
• quality attributes affecting delivered dose.

Transdermal products can require more than conventional systemic pharmacokinetic comparison. The applicant may need to establish adhesion, spray pattern, droplet or particle characteristics, drying time, residual drug, dose uniformity and comparative skin permeation.[3]

505(b)(2) strategy

A 505(b)(2) product could pursue differentiated attributes such as:

• reduced ethanol concentration;
• an alternative penetration enhancer;
• a lower-transfer film;
• a smaller or more ergonomic actuator;
• an alternative application site;
• improved dose titration;
• a formulation designed for sensitive skin.

The 505(b)(2) route may support product differentiation but can increase development cost and regulatory exposure. It can also generate new method-of-use, formulation and device patents.

What formulation improvements create the strongest commercial opportunities?

1. Lower-transfer estradiol spray

Secondary transfer is a key practical concern with topical hormone products. Evamist labeling instructs users to allow the application site to dry and avoid contact by others, particularly children.[1]

A product that dries faster and leaves less transferable estradiol could support a meaningful commercial claim. Development targets include:

• reduced residual surface drug;
• faster dry time;
• lower wet-film tack;
• improved resistance to washing or incidental contact;
• reduced transfer after clothing contact.

The challenge is balancing low surface residue with adequate dermal deposition. Excessive film formation can trap estradiol at the surface rather than promote absorption.

2. Skin-tolerability formulation

Ethanol and penetration enhancers can create burning, erythema or dryness. A formulation using a lower alcohol level, a milder enhancer or a controlled-release polymer could target users who discontinue patches because of adhesion problems or gels because of transfer concerns.

Potential excipient candidates include glycols, fatty alcohols, medium-chain solvents, phospholipids and polymeric film formers. Each candidate requires testing for estradiol solubility, skin irritation, spray performance and systemic exposure.

3. Improved actuator and dose control

The product delivers a small amount of estradiol per actuation. Actuator design therefore has a direct effect on clinical reliability. Commercial improvements may include:

• reduced priming requirements;
• improved dose uniformity throughout container life;
• lockout mechanisms to prevent accidental actuation;
• dose counters;
• child-resistant packaging;
• packaging that reduces ethanol loss;
• improved orientation independence.

Device patents can create more durable protection than a simple excipient substitution if the actuator produces measurable performance benefits.

4. Lower-dose and titratable products

Evamist’s label allows dose adjustment based on symptom control, with one, two or three sprays used under the prescribing instructions.[1] A next-generation product could offer more controlled titration through:

• a lower-dose actuator;
• a calibrated multidose pump;
• dose-counting packaging;
• a formulation with more linear exposure across spray counts;
• a once-weekly or less frequent delivery format.

Dose titration can improve positioning for patients requiring the lowest effective estrogen exposure. It also creates opportunities for method-of-use and device protection.

5. Excipient substitution for supply-chain resilience

A manufacturer may seek alternatives to octisalate or a specific povidone grade because of:

• supplier concentration;
• regional regulatory restrictions;
• cost volatility;
• impurity control;
• manufacturing-scale limitations;
• changing consumer preferences concerning cosmetic ingredients.

A substitution strategy must preserve the product’s critical quality attributes. A technically acceptable excipient replacement may still require substantial regulatory work if it changes permeation, drying, transfer or local tolerability.

How does Evamist compare with estradiol patches and gels?

Attribute	Evamist spray	Estradiol patch	Estradiol gel
Application	Spray to forearm	Adhesive patch	Rubbed onto skin
Main vehicle issue	Ethanol evaporation and transfer	Adhesion and skin reaction	Drying time and transfer
Dosing control	Number of sprays	Patch strength and replacement interval	Measured gel quantity
Device dependence	High	Moderate	Low to moderate
Excipient differentiation	High	Adhesive matrix or reservoir	Solvent, polymer and penetration enhancer
Generic substitution risk	Moderate to high	High across patch products	High across gel products
Commercial differentiation	Spray convenience and no adhesive	Longer dosing interval	Familiar topical application

Evamist’s best positioning is for patients who prefer a spray and do not tolerate adhesive systems. Its weakest position is price competition against established estradiol patches and gels, especially where payer formularies treat delivery systems as interchangeable.

Which companies are challenging or competing with Evamist?

Competition comes from multiple categories rather than from a single direct rival:

• manufacturers of generic estradiol patches;
• producers of estradiol gels and emulsions;
• branded menopause-therapy companies;
• contract development and manufacturing organizations with topical spray platforms;
• specialty pharmaceutical companies pursuing transdermal hormone products.

Perrigo, Viatris, Teva, Sandoz and other generic manufacturers have commercial experience with topical or transdermal products, although participation in the specific estradiol spray market depends on current FDA approvals and supply status. The strongest direct competitor would be an ANDA product with equivalent metered-dose performance. The strongest indirect competitors are low-cost estradiol patches and gels.

What manufacturing and intellectual-property barriers affect commercialization?

Commercial production requires control of both formulation and device operations. Key manufacturing controls include:

• estradiol assay and impurity profile;
• ethanol and octisalate content;
• viscosity and density;
• spray mass per actuation;
• delivered-dose uniformity;
• priming and repriming performance;
• container-closure integrity;
• actuator compatibility;
• microbial and particulate controls;
• stability under temperature and humidity stress.

Ethanol-rich systems require controls for evaporation and fill-volume loss. Packaging must limit solvent loss while maintaining reliable actuation. The manufacturing process may be patentable where it produces a specific dose-uniformity profile or controls estradiol crystallization.

Geographic protection should be reviewed separately in the United States, European Union, Canada, Japan and major emerging markets. A U.S. Orange Book listing does not establish protection in other jurisdictions. European and national patent registers may contain formulation, device or manufacturing claims that are absent from the U.S. record.

What is the revenue opportunity for an Evamist follow-on product?

The commercial opportunity is strongest for a differentiated product, not a commodity copy. Revenue potential depends on:

• current brand and generic prescription volume;
• reimbursement for transdermal estrogen products;
• wholesale acquisition price;
• payer substitution rules;
• direct competitors at launch;
• manufacturing cost per unit;
• patent litigation timing;
• availability of other low-dose menopause therapies.

A low-cost generic spray could obtain rapid substitution if it achieves therapeutic equivalence and a reliable supply position. A 505(b)(2) product could command a premium if it demonstrates lower transfer, improved tolerability or better dosing control. The latter strategy requires stronger clinical and commercial evidence but can avoid direct price competition with basic estradiol generics.

Key Takeaways

• Evamist is an estradiol transdermal spray using ethanol, octisalate and povidone.
• The formulation’s value comes from controlled skin delivery, rapid drying and metered dosing.
• Generic development must address formulation, actuator performance, delivered-dose uniformity and transfer behavior.
• Estradiol has no biosimilar risk; competition is through ANDA or 505(b)(2) pathways.
• The most attractive innovation areas are lower-transfer films, improved skin tolerability, dose counters, better actuators and lower-dose titration.
• Orange Book patents, device claims and later formulation patents must be analyzed separately from the expired exclusivity surrounding estradiol itself.
• Patches and gels are major indirect competitors and may limit pricing power for a direct spray generic.
• The strongest commercial strategy is a differentiated transdermal platform with measurable performance advantages.

FAQs About Evamist Excipient and Commercial Strategy

Can octisalate be removed from an Evamist generic formulation?

Yes, but removal could alter estradiol solubility, skin permeation, drying behavior and systemic exposure. The regulatory consequences depend on the extent of formulation and performance differences.

Is Evamist interchangeable with estradiol gel?

No automatic clinical or regulatory interchangeability should be assumed. The products use different vehicles, application procedures, dosing systems and transfer profiles.

Can a manufacturer patent a new Evamist excipient combination?

Potentially. Patentability would depend on novelty, non-obviousness and technical evidence, such as improved exposure, reduced transfer, better tolerability or superior dose uniformity.

Does a spray actuator create separate patent risk from the formulation?

Yes. Claims may cover the actuator, dose-metering mechanism, container-closure system, priming process, spray pattern or dose counter independently of the excipient composition.

What is the most defensible commercial improvement for an Evamist follow-on?

A lower-transfer, fast-drying formulation combined with reliable dose counting and consistent actuation offers the clearest opportunity for product differentiation.

References

1. U.S. Food and Drug Administration. (2019). Evamist estradiol transdermal spray prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Transdermal and topical delivery systems: Product development and quality considerations.